Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

The DAPA-DIET study : metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes mellitus and obesity—a longitudinal cohort study

Tools
- Tools
+ Tools

Hanson, Petra, Randeva, Harpal S., Cuthbertson, D., O'Hare, Paul J., Parsons, Nicholas R., Chatha, Kamaljit , Reidy, G., Weickert, Martin O. and Barber, Thomas M. (2022) The DAPA-DIET study : metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes mellitus and obesity—a longitudinal cohort study. Endocrinology, Diabetes & Metabolism, 5 (6). e381. doi:10.1002/edm2.381 ISSN 2398-9238. [ 🗎 Public]. [ (✓) hoa:511 ]

[img]
Preview
PDF
WRAP-The-DAPA‐DIET-study-metabolic-Dapagliflozin-dietary-22.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (1557Kb) | Preview
Official URL: https://doi.org/10.1002/edm2.381

Request Changes to record.

Abstract

The cardio-renal benefits of sodium glucose-like transporter 2 inhibitor (SGLT2i) therapies have been demonstrated in patients with and without type 2 diabetes. However, no studies have explored the long-term metabolic effects of SGLT2i, combined with dietary carbohydrate restriction. Our primary objective was to describe long-term changes in weight, energy expenditure, appetite and body composition after 12 months of Dapagliflozin therapy, with carbohydrate restriction, in people with type 2 diabetes and obesity. Our secondary objective was to assess changes in adiponectin and leptin.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Type 2 diabetes, Type 2 diabetes -- Diet therapy, Type 2 diabetes -- Treatment, Obesity , Reducing diets , Obesity -- Treatment
Journal or Publication Title: Endocrinology, Diabetes & Metabolism
Publisher: John Wiley & Sons
ISSN: 2398-9238
Official Date: November 2022
Dates:
DateEvent
November 2022Published
20 October 2022Available
24 September 2022Accepted
Volume: 5
Number: 6
Article Number: e381
DOI: 10.1002/edm2.381
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons)
Date of first compliant deposit: 1 November 2022
Date of first compliant Open Access: 1 November 2022
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDAstraZenecahttp://dx.doi.org/10.13039/100004325
Related URLs:
  • Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us